Brokerages Set Mirati Therapeutics, Inc. (NASDAQ:MRTX) Price Target at $60.00

Shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX – Get Free Report) have earned an average recommendation of “Hold” from the fourteen brokerages that are currently covering the firm, MarketBeat Ratings reports. Eleven analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price […]

Related Keywords

United States ,Jamie Christensen ,Leerink Partnrs ,Benjamin Hickey ,Stifel Nicolaus ,Acadian Asset Management ,Nasdaq ,Mirati Therapeutics Inc ,Citigroup ,Quadrant Capital Group ,Bluepath Capital Management ,Securities Exchange Commission ,First Horizon Advisors Inc ,Mirati Therapeutics ,Get Free Report ,Marketbeat Ratings ,Exchange Commission ,Capital Group ,Horizon Advisors ,Asset Management ,Get Free ,Mirati Therapeutics Daily ,Nasdaq Mrtx ,Mrtx ,Medical ,Ratings ,Consensus ,